Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Director Edward Moore Kennedy Jr. of Arvinas reported significant equity transactions on June 25, 2025:
- Acquired 16,025 restricted stock units (RSUs) at $0, bringing direct ownership to 39,430 shares
- Granted 23,105 stock options with exercise price of $7.80, expiring June 24, 2035
- Maintains indirect ownership of 29,333 shares through Edward M. Kennedy Jr. 2011 Trusts For Children
Both RSUs and options vest in full on the earlier of June 25, 2026, or the first board meeting after the next annual stockholder meeting, contingent on continued service. The RSUs represent rights to receive common stock upon settlement without consideration. This compensation package aligns with standard director equity incentives and demonstrates long-term commitment to the company.
Arvinas Director Everett Cunningham received significant equity compensation on June 25, 2025, consisting of two key components:
- 16,025 Restricted Stock Units (RSUs) granted at $0, increasing total direct common stock ownership to 26,045 shares
- 23,105 Stock Options with exercise price of $7.80, expiring June 24, 2035
Both the RSUs and stock options will fully vest on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting, contingent on Cunningham's continued service. The RSUs represent rights to receive common stock at no cost upon settlement, while the options provide purchase rights at the specified strike price. This compensation structure aligns the director's interests with long-term shareholder value.
Insider Trading Activity Report: Leslie V. Norwalk, Director of Arvinas (NASDAQ: ARVN), received significant equity compensation on June 25, 2025. The transaction includes:
- Restricted Stock Units (RSUs): Granted 16,025 RSUs that convert to common stock at no cost, vesting on June 25, 2026 or at the first board meeting after the next annual stockholder meeting
- Stock Options: Awarded 23,105 options with exercise price of $7.80, expiring June 24, 2035, following the same vesting schedule as RSUs
Following these transactions, Norwalk directly owns 26,045 shares of common stock and 23,105 stock options. The equity grants appear to be part of the company's director compensation program, with both RSUs and options structured with one-year cliff vesting, subject to continued service.
Form 4 filed for Arvinas, Inc. (ARVN) discloses that Chief Financial Officer Andrew Saik executed a Rule S sale of 5,700 common shares on 24 June 2025 at a price of $7.61 per share. The transaction was automatic and solely to cover tax-withholding obligations related to the vesting of 25 % of restricted stock units granted on 24 June 2024. Following the sale, Saik retains beneficial ownership of 164,401 shares, held directly. No derivative transactions were reported. The filing reflects a routine administrative sale rather than an open-market disposition, and it does not alter Saik’s officer status or ownership structure.
Arvinas, Inc. (NASDAQ: ARVN) — Form 144 filed for proposed insider sale
The notice, dated 24 June 2025, discloses an intent to sell up to 5,927 shares of Arvinas common stock through broker Morgan Stanley Smith Barney LLC. At an aggregate market value of US$43,593 and with 72,991,390 shares outstanding, the sale represents roughly 0.008 % of the company’s equity float.
The securities were acquired the same day via the vesting of restricted stock units issued by Arvinas, with no cash consideration. The filer reports no other sales in the previous three months and signs the customary representation that no undisclosed material adverse information is known.
Form 144 is a notice only; it does not obligate execution of the transaction. Given the small size relative to total shares outstanding and the lack of additional material disclosures, the filing appears routine and is unlikely to have a meaningful impact on Arvinas’ capital structure, operations, or near-term share price dynamics.
Arvinas, Inc. (ARVN) – Form 4 insider transaction filed 06/18/2025
Chief Scientific Officer Angela M. Cacace disclosed the sale of 2,583 common shares on 06/17/2025 at $7.49 per share. The company executed this sale automatically to satisfy tax-withholding obligations arising from the vesting and settlement of 50% of restricted stock units (RSUs) granted on 06/17/2024.
Post-transaction, the executive retains 154,248 shares held directly. No new options, warrants, or other derivative securities were reported, and the filing does not reference a Rule 10b5-1 trading plan.
Because the sale was issuer-directed and linked to tax withholding rather than discretionary portfolio rebalancing, it carries limited signaling value regarding the executive’s outlook. The relatively small size (≈1.7% of her holdings) further supports a neutral interpretation for investors.